Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Anaesthesiologie ; 72(2): 113-120, 2023 02.
Artículo en Alemán | MEDLINE | ID: mdl-36477906

RESUMEN

Percutaneous hepatic melphalan perfusion (PHMP) is a last-line treatment of inoperable primary or secondary liver tumors. Selective perfusion and saturation (chemosaturation) of the liver with the chemotherapeutic agent melphalan is performed via catheterization of the hepatic artery without affecting the rest of the body with its cytotoxic properties. Using an extracorporeal circulation and balloon occlusion of the inferior vena cava, the venous hepatic blood is filtered and returned using a bypass procedure. During the procedure, considerable circulatory depression and coagulopathy are frequent. The purpose of this article is to review the anesthesiological and postprocedural management of patients undergoing PHMP with consideration of the pitfalls and special circumstances.


Asunto(s)
Antineoplásicos , Melfalán , Humanos , Melfalán/efectos adversos , Quimioterapia del Cáncer por Perfusión Regional/efectos adversos , Antineoplásicos/uso terapéutico , Circulación Extracorporea , Perfusión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...